BioStock: Cereno Scientific signs CRO for phase II study

Yesterday, Cereno Scientific announced the signing of a letter of intent with the global contract research organisation Worldwide Clinical Trials. The partnership signals that final preparations for a phase II study with their epigenetic modulator CS1 for treating Pulmonary Arterial Hypertension are well underway, and it comes in conjunction with the initiation of a clinical trial application to the FDA.

Read the full article at biostock.se:

https://www.biostock.se/en/cereno-scientific-signs-cro-for-phase-ii-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se